Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists

Chen Chen, Fabio C. Tucci, Wanlong Jiang, Joe A. Tran, Beth A. Fleck, Sam R. Hoare, Jenny Wen, Takung Chen, Michael Johns, Stacy Markison, Alan C. Foster, Dragan Marinkovic, Caroline W. Chen, Melissa Arellano, John Harman, John Saunders, Haig Bozigian, Daniel Marks

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A series of 2-piperazine-α-isopropylbenzylamine derivatives were synthesized and characterized as melanocortin-4 receptor (MC4R) antagonists. Attaching an amino acid to benzylamines 7 significantly increased their binding affinity, and the resulting compounds 8-12 bound selectively to MC4R over other melanocortin receptor subtypes and behaved as functional antagonists. These compounds were also studied for their permeability using Caco-2 cell monolayers and metabolic stability in human liver microsomes. Most compounds exhibited low permeability and high efflux ratio possibly due to their high molecular weights. They also showed moderate metabolic stability which might be associated with their moderate to high lipophilicity. Pharmacokinetic properties of these MC4R antagonists, including brain penetration, were studied in mice after oral and intravenous administrations. Two compounds identified to possess high binding affinity and selectivity, 10d and 11d, were studied in a murine cachexia model. After intraperitoneal (ip) administration of 1 mg/kg dose, mice treated with 10d had significantly more food intake and weight gain than the control animals, demonstrating efficacy by blocking the MC4 receptor. Similar in vivo effects were also observed when 11d was dosed orally at 20 mg/kg. These results provide further evidence that a potent and selective MC4R antagonist has potential in the treatment of cancer cachexia.

Original languageEnglish (US)
Pages (from-to)5606-5618
Number of pages13
JournalBioorganic and Medicinal Chemistry
Volume16
Issue number10
DOIs
StatePublished - May 15 2008

Fingerprint

Receptor, Melanocortin, Type 4
Pharmacokinetics
Pharmacology
Derivatives
Cachexia
Permeability
Benzylamines
Melanocortin Receptors
Caco-2 Cells
Liver Microsomes
Intravenous Administration
Liver
Weight Gain
Oral Administration
Monolayers
Brain
Animals
Eating
Molecular Weight
Molecular weight

Keywords

  • Antagonist
  • Cachexia
  • Melanocortin-4 receptor
  • Pharmacokinetics
  • SAR

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. / Chen, Chen; Tucci, Fabio C.; Jiang, Wanlong; Tran, Joe A.; Fleck, Beth A.; Hoare, Sam R.; Wen, Jenny; Chen, Takung; Johns, Michael; Markison, Stacy; Foster, Alan C.; Marinkovic, Dragan; Chen, Caroline W.; Arellano, Melissa; Harman, John; Saunders, John; Bozigian, Haig; Marks, Daniel.

In: Bioorganic and Medicinal Chemistry, Vol. 16, No. 10, 15.05.2008, p. 5606-5618.

Research output: Contribution to journalArticle

Chen, C, Tucci, FC, Jiang, W, Tran, JA, Fleck, BA, Hoare, SR, Wen, J, Chen, T, Johns, M, Markison, S, Foster, AC, Marinkovic, D, Chen, CW, Arellano, M, Harman, J, Saunders, J, Bozigian, H & Marks, D 2008, 'Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists', Bioorganic and Medicinal Chemistry, vol. 16, no. 10, pp. 5606-5618. https://doi.org/10.1016/j.bmc.2008.03.072
Chen, Chen ; Tucci, Fabio C. ; Jiang, Wanlong ; Tran, Joe A. ; Fleck, Beth A. ; Hoare, Sam R. ; Wen, Jenny ; Chen, Takung ; Johns, Michael ; Markison, Stacy ; Foster, Alan C. ; Marinkovic, Dragan ; Chen, Caroline W. ; Arellano, Melissa ; Harman, John ; Saunders, John ; Bozigian, Haig ; Marks, Daniel. / Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. In: Bioorganic and Medicinal Chemistry. 2008 ; Vol. 16, No. 10. pp. 5606-5618.
@article{de3fe5ca04db467194cf3235bf9f4f59,
title = "Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists",
abstract = "A series of 2-piperazine-α-isopropylbenzylamine derivatives were synthesized and characterized as melanocortin-4 receptor (MC4R) antagonists. Attaching an amino acid to benzylamines 7 significantly increased their binding affinity, and the resulting compounds 8-12 bound selectively to MC4R over other melanocortin receptor subtypes and behaved as functional antagonists. These compounds were also studied for their permeability using Caco-2 cell monolayers and metabolic stability in human liver microsomes. Most compounds exhibited low permeability and high efflux ratio possibly due to their high molecular weights. They also showed moderate metabolic stability which might be associated with their moderate to high lipophilicity. Pharmacokinetic properties of these MC4R antagonists, including brain penetration, were studied in mice after oral and intravenous administrations. Two compounds identified to possess high binding affinity and selectivity, 10d and 11d, were studied in a murine cachexia model. After intraperitoneal (ip) administration of 1 mg/kg dose, mice treated with 10d had significantly more food intake and weight gain than the control animals, demonstrating efficacy by blocking the MC4 receptor. Similar in vivo effects were also observed when 11d was dosed orally at 20 mg/kg. These results provide further evidence that a potent and selective MC4R antagonist has potential in the treatment of cancer cachexia.",
keywords = "Antagonist, Cachexia, Melanocortin-4 receptor, Pharmacokinetics, SAR",
author = "Chen Chen and Tucci, {Fabio C.} and Wanlong Jiang and Tran, {Joe A.} and Fleck, {Beth A.} and Hoare, {Sam R.} and Jenny Wen and Takung Chen and Michael Johns and Stacy Markison and Foster, {Alan C.} and Dragan Marinkovic and Chen, {Caroline W.} and Melissa Arellano and John Harman and John Saunders and Haig Bozigian and Daniel Marks",
year = "2008",
month = "5",
day = "15",
doi = "10.1016/j.bmc.2008.03.072",
language = "English (US)",
volume = "16",
pages = "5606--5618",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists

AU - Chen, Chen

AU - Tucci, Fabio C.

AU - Jiang, Wanlong

AU - Tran, Joe A.

AU - Fleck, Beth A.

AU - Hoare, Sam R.

AU - Wen, Jenny

AU - Chen, Takung

AU - Johns, Michael

AU - Markison, Stacy

AU - Foster, Alan C.

AU - Marinkovic, Dragan

AU - Chen, Caroline W.

AU - Arellano, Melissa

AU - Harman, John

AU - Saunders, John

AU - Bozigian, Haig

AU - Marks, Daniel

PY - 2008/5/15

Y1 - 2008/5/15

N2 - A series of 2-piperazine-α-isopropylbenzylamine derivatives were synthesized and characterized as melanocortin-4 receptor (MC4R) antagonists. Attaching an amino acid to benzylamines 7 significantly increased their binding affinity, and the resulting compounds 8-12 bound selectively to MC4R over other melanocortin receptor subtypes and behaved as functional antagonists. These compounds were also studied for their permeability using Caco-2 cell monolayers and metabolic stability in human liver microsomes. Most compounds exhibited low permeability and high efflux ratio possibly due to their high molecular weights. They also showed moderate metabolic stability which might be associated with their moderate to high lipophilicity. Pharmacokinetic properties of these MC4R antagonists, including brain penetration, were studied in mice after oral and intravenous administrations. Two compounds identified to possess high binding affinity and selectivity, 10d and 11d, were studied in a murine cachexia model. After intraperitoneal (ip) administration of 1 mg/kg dose, mice treated with 10d had significantly more food intake and weight gain than the control animals, demonstrating efficacy by blocking the MC4 receptor. Similar in vivo effects were also observed when 11d was dosed orally at 20 mg/kg. These results provide further evidence that a potent and selective MC4R antagonist has potential in the treatment of cancer cachexia.

AB - A series of 2-piperazine-α-isopropylbenzylamine derivatives were synthesized and characterized as melanocortin-4 receptor (MC4R) antagonists. Attaching an amino acid to benzylamines 7 significantly increased their binding affinity, and the resulting compounds 8-12 bound selectively to MC4R over other melanocortin receptor subtypes and behaved as functional antagonists. These compounds were also studied for their permeability using Caco-2 cell monolayers and metabolic stability in human liver microsomes. Most compounds exhibited low permeability and high efflux ratio possibly due to their high molecular weights. They also showed moderate metabolic stability which might be associated with their moderate to high lipophilicity. Pharmacokinetic properties of these MC4R antagonists, including brain penetration, were studied in mice after oral and intravenous administrations. Two compounds identified to possess high binding affinity and selectivity, 10d and 11d, were studied in a murine cachexia model. After intraperitoneal (ip) administration of 1 mg/kg dose, mice treated with 10d had significantly more food intake and weight gain than the control animals, demonstrating efficacy by blocking the MC4 receptor. Similar in vivo effects were also observed when 11d was dosed orally at 20 mg/kg. These results provide further evidence that a potent and selective MC4R antagonist has potential in the treatment of cancer cachexia.

KW - Antagonist

KW - Cachexia

KW - Melanocortin-4 receptor

KW - Pharmacokinetics

KW - SAR

UR - http://www.scopus.com/inward/record.url?scp=43749088040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749088040&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2008.03.072

DO - 10.1016/j.bmc.2008.03.072

M3 - Article

C2 - 18417348

AN - SCOPUS:43749088040

VL - 16

SP - 5606

EP - 5618

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 10

ER -